SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Ariad Pharmaceuticals, Inc. Announces Initial Data on AP26113, Investigational Dual-Inhibitor of ALK and EGFR, to be Presented at the ESMO 2012 Congress of the European Society for Medical Oncology